Trial Details
RECRUITINGBasic Information
| Clinical ID | c1749 |
|---|---|
| Identifier | NCT05598684 |
| Trial Title | SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Crohn Disease|Ulcerative Colitis|Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis |
| Interventions | - |
Participant Information
| Sponsor | Fresenius Kabi, France |
|---|---|
| City | Alès |
| Country/Region | France |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | OBSERVATIONAL |
|---|---|
| Phase | - |
Time Information
| Start Date | 2022-11-24 |
|---|---|
| Primary Completion Date | 2025-09-30 |
| Completion Date | 2025-12-30 |